Ling Pan

机构：Jinyintan Hospital, Huazhong University of Science and Technology · ORCID：0000-0003-0650-7585

发表论文 89 篇 · 总被引 1738 次 · h-index 19

代表论文

• Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial (2023 · BMC Cancer · 被引 17)
• Ginkgo biloba Extract 50 (GBE50) Exerts Antifibrotic and Antioxidant Effects on Pulmonary Fibrosis in Mice by Regulating Nrf2 and TGF-β1/Smad Pathways (2023 · Applied Biochemistry and Biotechnology · 被引 10)
• Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study (2024 · Clinical Lymphoma Myeloma & Leukemia · 被引 9)
• Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review (2024 · Frontiers in Oncology · 被引 8)
• First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study (2023 · Blood · 被引 8)
• ExerGeneDB: A physical exercise-regulated differential gene expression database (2025 · Journal of sport and health science/Journal of Sport and Health Science · 被引 6)